ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: a meta-analysis

Adela Madrid-Paredes, Maria Luisa Canadas Garre, Antonio Sanchez-Pozo, Manuela Exposito Ruiz, Miguel Angel Calleja Hernandez

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
313 Downloads (Pure)


The ABCB1 gene encodes the P-glycoprotein, an efflux pump for some antineoplastic agents which acts as a resistance mechanism to chemotherapy. Three SNPs (C3435T, C1236T and G2677T/A), are the most widely studied in ABCB1. The inconsistent conclusions about the association of these polymorphisms and the response to chemotherapy in breast cancer (BC) patients prompted us to conduct a meta-analysis. A total of nine (770 patients), five (566 patients) and three studies (367 patients) relating the ABCB1 C3435T, C1236T and G2677T/A polymorphisms respectively, were included. The main analysis revealed a lack of association between ABCB1 polymorphisms and response to chemotherapy in every genetic model: C3435T (dominant OR: 0.888; 95%CI: 0.558-1.413), C1236T (dominant OR: 1.968; 95%CI: 0.609-6.362) and G2677T/A (GG vs GT+GA+TT+TA+AA OR: 0.854; 95%CI: 0.418-1.744). Stratification by ethnicity, cancer type and response criteria did not change the pattern of results.The available evidence indicates that three polymorphisms within ABCB1; C3435T, C1236T and G2677T/A, cannot be considered a reliable predictor of response to chemotherapy in BC patients.
Original languageEnglish
JournalSurgical Oncology
Early online date21 Sep 2017
Publication statusEarly online date - 21 Sep 2017


Dive into the research topics of 'ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: a meta-analysis'. Together they form a unique fingerprint.

Cite this